2026 Optometry Educational Dinner (August)
2026 Optometry Educational Dinner (August)
Proudly Supported by the Layton Vision Foundation

2026 Optometry Educational Dinner (August)

Wade Core Function Centre (Carina Leagues Club) (Carina , QLD)
Wednesday, 5 August 2026 6:30 pm
84 days away
All Ages
Educational

Tickets{{ currencyFormat(total) }}

Please select a ticket
{{ showMustPurchaseAdditionalTicketsAlertMessage }}
Your cart has expired
Access / promo code provided is invalid
Optometrist
$0.00
$0.00
{{ requestedInventory['a2f5305b-225d-4b61-8d57-d55413b98d60'] }}
GP / Other
$0.00
$0.00
{{ requestedInventory['d330f71a-a8ce-4fdc-b387-62fe40ce202d'] }}
A donation supports the scientists of the Layton Vision Research team to find a cure for blinding diseases and allows the Layton Vision Foundation to continue to provide educational events to Optometrists and GPs.
$50 Donation
$51.00
Tax Deductible Donation
$51.00
{{ requestedInventory['b9bbda78-cb01-406f-8d44-1607df225aea'] }}
$20 Donation
$20.40
Tax Deductible Donation
$20.40
{{ requestedInventory['89a6a9c8-a62f-4987-a673-bd5efdde0f53'] }}
$10 Donation
$10.20
Tax Deductible Donation
$10.20
{{ requestedInventory['2461f74c-f1c9-4668-a3d7-cf22cde97b43'] }}
Added to cart
{{ collectionCartTicketCount }} tickets in your cart View cart
TOPIC: Progress in Geograpic Atrophy. Treatment approvals in Australia.

Our Presenter – Professor Christopher Layton:
Professor Christopher Layton (Dr Chris) is a private Clinical Ophthalmologist, Rhodes Scholar and a national leader in innovative ophthalmology. His expertise is in macular disease, lens surgery and minimally invasive glaucoma interventions. He completed optometry at QUT, ophthalmology in Queensland, Oxford and London, subspecialty training in retinal disease at the Royal Brisbane Hospital and holds a PhD in diabetic retinopathy from Oxford University. Professor Layton is the founding director of the LVF Ophthalmology Research Centre. He is also CEO of Ocugene, a Queensland based biotech start-up which is commercialising his gene therapy technology targeting macular degeneration, uveitis and choroidal melanoma.